

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

<p>1. LICENSEE/LOCATION INSPECTED:</p> <p>Aspirus Grand View N10561 Grand View Lane Ironwood, MI 49938-9359</p> <p>REPORT NUMBER(S) 13-01</p>	<p>2. NRC/REGIONAL OFFICE</p> <p>Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352</p>	
<p>3. DOCKET NUMBER(S)</p> <p>030-35898</p>	<p>4. LICENSE NUMBER(S)</p> <p>21-32342-01</p>	<p>5. DATE(S) OF INSPECTION</p> <p>July 23, 2013</p>

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:



- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		7/23/13
BRANCH CHIEF	Aaron T. McCraw		8/7/13

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Aspirus Grand View N10561 Grand View Lane Ironwood, MI 49938-9359 REPORT NUMBER(S) 13-01	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
--	---

3. DOCKET NUMBER(S) 030-35898	4. LICENSE NUMBER(S) 21-32342-01	5. DATE(S) OF INSPECTION July 23, 2013
--------------------------------------	---	---

6. INSPECTION PROCEDURES USED 87131	7. INSPECTION FOCUS AREAS 03.01-03.07
--	--

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02121	2. PRIORITY 5	3. LICENSEE CONTACT D. Cataldo, DO, RSO	4. TELEPHONE NUMBER (906) 932-6217
---------------------------------	----------------------	--	---

Main Office Inspection Next Inspection Date: 07/23/2018

Field Office Inspection _____

Temporary Job Site Inspection _____

PROGRAM SCOPE

The licensee was a medical institution authorized by the license to use any byproduct material as needed, for any study permitted by 10 CFR 35.100, and 35.200 at the location specified on the license.

The nuclear medicine department was staffed with one full-time nuclear medicine technologist (NMT). The NMT administered an average of 2-3 cardiac studies and 1-2 other studies per day. No Xe-133 is used for lung studies and I-123 is used for uptake studies. The nuclear medicine department received unit doses from a nearby Wisconsin nuclear pharmacy. All waste was either held for decay-in-storage (DIS) or returned to the nuclear pharmacy as limited quantity shipments.

Performance Observations

The licensee's NMT (Mike Saubert) demonstrated/discussed: (1) survey meter use and calibrations; (2) package check-in procedures; (3) unit dosage prep and safe use; (4) wipe test counting; (5) waste handling; (6) sealed source inventories and leak tests; (7) routine security of licensed material; (8) dose calibrator tests; (9) quarterly safety program audits; (10) any contamination events (none); (11) HAZMAT refresher training (2011); (12) daily surveys and weekly wipe tests; and (13) dosimetry < 100 mrem DDE and 400 mrem SDE for 2011 and 2012.

The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.